Chen K, Borglund E, Postema E, Dunn A, Bourgeois F
Clin Trials. 2022; 19(4):442-451.
PMID: 35482320
PMC: 9378423.
DOI: 10.1177/17407745221093567.
Son K, Park S
Front Med (Lausanne). 2022; 9:869262.
PMID: 35433745
PMC: 9006612.
DOI: 10.3389/fmed.2022.869262.
McPhail M, McCabe C, Regier D, Bubela T
Healthc Policy. 2022; 17(3):81-90.
PMID: 35319446
PMC: 8935925.
DOI: 10.12927/hcpol.2022.26726.
Skydel J, Zhang A, Dhruva S, Ross J, Wallach J
Clin Trials. 2021; 18(4):488-499.
PMID: 33863236
PMC: 8292154.
DOI: 10.1177/17407745211005044.
Hooimeyer A, Bhasale A, Perry L, Fabbri A, Mohammad A, McEwin E
Pharmacol Res Perspect. 2020; 8(6):e00680.
PMID: 33169534
PMC: 7652786.
DOI: 10.1002/prp2.680.
Pharmaceutical Drugs of Uncertain Value, Lifecycle Regulation at the US Food and Drug Administration, and Institutional Incumbency.
Herder M
Milbank Q. 2019; 97(3):820-857.
PMID: 31407412
PMC: 6739605.
DOI: 10.1111/1468-0009.12413.
Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis.
Wallach J, Luxkaranayagam A, Dhruva S, Miller J, Ross J
BMC Med. 2019; 17(1):117.
PMID: 31203816
PMC: 6572730.
DOI: 10.1186/s12916-019-1344-3.
Analysis of Postapproval Clinical Trials of Therapeutics Approved by the US Food and Drug Administration Without Clinical Postmarketing Requirements or Commitments.
Skydel J, Luxkaranayagam A, Dhruva S, Ross J, Wallach J
JAMA Netw Open. 2019; 2(5):e193410.
PMID: 31074812
PMC: 6512282.
DOI: 10.1001/jamanetworkopen.2019.3410.
Physicians' Perspectives on FDA Approval Standards and Off-label Drug Marketing.
Kesselheim A, Woloshin S, Lu Z, Tessema F, Ross K, Schwartz L
JAMA Intern Med. 2019; 179(5):707-709.
PMID: 30667474
PMC: 6503563.
DOI: 10.1001/jamainternmed.2018.8121.
Timeliness of Postmarket Studies for New Pharmaceuticals Approved Between 2009 and 2012: a Cross-Sectional Analysis.
Wallach J, Egilman A, Ross J, Woloshin S, Schwartz L
J Gen Intern Med. 2018; 34(4):492-495.
PMID: 30543020
PMC: 6445841.
DOI: 10.1007/s11606-018-4779-x.
Completion Rate and Reporting of Mandatory Pediatric Postmarketing Studies Under the US Pediatric Research Equity Act.
Hwang T, Orenstein L, Kesselheim A, Bourgeois F
JAMA Pediatr. 2018; 173(1):68-74.
PMID: 30452498
PMC: 6583440.
DOI: 10.1001/jamapediatrics.2018.3416.
Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis.
Wallach J, Egilman A, Dhruva S, McCarthy M, Miller J, Woloshin S
BMJ. 2018; 361:k2031.
PMID: 29794072
PMC: 5967364.
DOI: 10.1136/bmj.k2031.
Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review.
Pease A, Krumholz H, Downing N, Aminawung J, Shah N, Ross J
BMJ. 2017; 357:j1680.
PMID: 28468750
PMC: 5421452.
DOI: 10.1136/bmj.j1680.
FDA Policy and Cardiovascular Medicine.
Ross J, Kesselheim A
Circulation. 2015; 132(12):1136-45.
PMID: 26391294
PMC: 4586041.
DOI: 10.1161/CIRCULATIONAHA.114.010295.
Industry Support of Medical Research: Important Opportunity or Treacherous Pitfall?.
Tierney W, Meslin E, Kroenke K
J Gen Intern Med. 2015; 31(2):228-233.
PMID: 26307387
PMC: 4720652.
DOI: 10.1007/s11606-015-3495-z.
Inconsistencies among European Union pharmaceutical regulator safety communications: a cross-country comparison.
Zeitoun J, Lefevre J, Downing N, Bergeron H, Ross J
PLoS One. 2014; 9(10):e109100.
PMID: 25333986
PMC: 4204813.
DOI: 10.1371/journal.pone.0109100.
Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012.
Downing N, Aminawung J, Shah N, Krumholz H, Ross J
JAMA. 2014; 311(4):368-77.
PMID: 24449315
PMC: 4144867.
DOI: 10.1001/jama.2013.282034.
Risk evaluation and monitoring in multiple sclerosis therapeutics.
Clanet M, Wolinsky J, Ashton R, Hartung H, Reingold S
Mult Scler. 2013; 20(10):1306-11.
PMID: 24293456
PMC: 4232326.
DOI: 10.1177/1352458513513207.
A new approach to psychiatric drug approval in Europe.
Barbui C, Bighelli I
PLoS Med. 2013; 10(10):e1001530.
PMID: 24143137
PMC: 3797138.
DOI: 10.1371/journal.pmed.1001530.
